US Executive Compensation Proxy SEC Filings — April 23, 2026

23-04-2026

Chimera Investment Corp (CIM), a Real Estate Investment Trust, filed its DEF 14A definitive proxy statement on April 23, 2026, for the annual stockholder meeting on June 10, 2026. Shareholders will vote to elect three Class I directors—Kevin G. Chavers (62), Gerard Creagh (68), and Susan Mills (66)—to serve until the 2029 annual meeting; all are independent and renominated for continuing service. The board has seven members total (six independent), with continuing Class II directors Debra W. Still (73, independent) and Phillip J. Kardis (64, non-independent), and Class III directors Brian P. Reilly (66, independent) and Cynthia B. Walsh (61, independent).

• ·Fiscal year end: December 31
• ·Company address: One Rockefeller Plaza, 32nd Floor, New York, NY 10020
• ·Phone: 212-626-2300
• ·State of incorporation: NY
• ·Director tenures: Kevin G. Chavers since June 2021; Gerard Creagh since April 2010; Susan Mills since November 2023; Debra W. Still since March 2018; Phillip J. Kardis since December 2022; Brian P. Reilly since July 2019; Cynthia B. Walsh since December 2024
• ·Proxy references compensation data for PEOs including Phillip J. Kardis and prior (Marria) across 2021-2025, and non-PEO NEOs, but specific values not detailed in filing excerpt

23-04-2026

Reddit, Inc. (RDDT) filed its DEF 14A Proxy Statement on April 23, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 8, 2026 (record date April 13, 2026), proposing the election of eight directors including CEO Steven Huffman, ratification of KPMG LLP as independent auditors for the year ending December 31, 2026, and an advisory vote to approve Named Executive Officer compensation. The Board recommends voting FOR all three proposals and highlights strong governance practices such as a majority-independent board, declassified structure, and fully independent committees. No financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Annual Meeting is virtual at www.virtualshareholdermeeting.com/RDDT2026.
• ·Director service start dates: Steven Huffman (July 2015), Sarah Farrell (May 2024), Patricia Fili-Krushel (January 2022), Porter Gale (April 2019), David Habiger (November 2022), Steven O. Newhouse (March 2024), Robert A. Sauerberg Jr. (April 2012), Michael Seibel (July 2020).
• ·Director ages as of March 31, 2026: Steven Huffman (42), Sarah Farrell (35), Patricia Fili-Krushel (72), Porter Gale (59), David Habiger (57), Steven O. Newhouse (69), Robert A. Sauerberg Jr. (65), Michael Seibel (43).

23-04-2026

American Strategic Investment Co.'s DEF 14A proxy statement discloses 2025 compensation for named executive officers (NEOs), with new CEO Nicholas S. Schorsch, Jr. receiving total compensation of $906,047 including $356,669 salary, $298,949 bonus, and $199,200 in stock awards; however, former CEO Michael Anderson's pay sharply declined to $175,255 from $544,579 in 2024 following his March 2025 resignation, while CFO Michael LeSanto's total rose modestly to $365,276 from $342,377. The company granted 26,000 restricted shares to NEOs in 2025 and reports no employees, omitting CEO pay ratio. Independent directors received average total compensation around $117,000-$172,000, including $30,000-$55,000 retainers and $64,327 stock awards.

• ·Closing price of Common Stock on Dec 31, 2025: $8.29 per share.
• ·No contractual arrangements for potential payments upon termination or change in control for NEOs.
• ·No compensation policies likely to have material adverse risk effect.
• ·Michael Anderson resigned as CEO effective March 19, 2025; Joseph Marnikovic resigned as CFO effective April 4, 2024.
• ·Aggregate 162,642 shares issued or subject to awards under 2020 Equity Plan as of Dec 31, 2025.
• ·During 2025, 1,158 shares vested for Michael LeSanto with fair value $12,526.23.

23-04-2026

OPAL Fuels Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 17, 2026, at 10:30 am ET, where shareholders will vote on the election of eight directors and the ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 22, 2026, with 30,357,544 shares of Class A common stock (1 vote each), 121,500,000 shares of Class B common stock (1 vote each), and 22,899,037 shares of Class D common stock (5 votes each) outstanding, totaling approximately 266,352,729 votes. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Voting methods: by mail, telephone (until June 16, 2026, 11:59 PM ET), internet (until June 16, 2026, 11:59 PM ET), or during virtual meeting.
• ·Proposal 1 (director election) requires plurality vote; Proposal 2 (auditor ratification) requires majority of voting power present.
• ·Proxy materials available at https://www.cstproxy.com/opalfuels/2026.
• ·Fiscal year reference: ended December 31, 2025; auditor for year ending December 31, 2026.

23-04-2026

Westrock Coffee Company's DEF 14A proxy statement details the 2026 Annual Meeting on June 5, 2026 (virtual at www.virtualshareholdermeeting.com/WEST2026), proposing the election of four Class I directors (Mark A. Edmunds, Joe T. Ford, Kenneth M. Parent, Oluwatoyin Umesiri) and ratification of PricewaterhouseCoopers LLP as auditors for FY 2026. The company emphasizes strong governance with 8 of 10 independent directors, separate Chairman and CEO roles, independent committees, and a phase-out of the classified board by 2028; no material weaknesses or controversies noted. As of the April 6, 2026 record date, 97,557,962 common shares and 23,510,527 Series A Convertible Preferred Stock shares (convertible 1:1 to common) were outstanding.

• ·Voting: Common and Series A Preferred Stock vote together as single class (1 vote per share); Preferred convertible 1:1 to common
• ·Board recommendations: FOR all four director nominees and FOR auditor ratification
• ·Governance: Independent Lead Director; Non-management directors meet regularly without management; No perquisites or post-retirement benefits for directors
• ·Proxy materials available at https://investors.westrockcoffee.com and www.proxyvote.com; Notice mailed April 23, 2026

23-04-2026

Medline Inc. reported strong FY2025 performance with net sales of $28.4 Billion, up 11.5% YoY, organic sales growth of 10.5% YoY, adjusted EBITDA of $3.5 Billion up 3.2% YoY, net cash from operating activities of $1.7 Billion, and free cash flow of $1.3 Billion. However, net income declined 3.6% YoY to $1.2 Billion. The 2026 Proxy Statement seeks election of 12 directors, including CEO James M. Boyle, and advisory approval of executive compensation tied to pay-for-performance.

• ·9 of 12 director nominees are independent.
• ·Sustainability Report released in September 2025, prepared per SASB standards for Medical Equipment and Supplies and Healthcare Distributors.
• ·Two segments: Medline Brand and Supply Chain Solutions.
• ·Over 1,600 active Prime Vendor relationships.

23-04-2026

Inseego Corp. filed its DEF 14A proxy statement for the Annual Meeting of Stockholders on June 16, 2026, at 10:00 a.m. PT in San Diego, CA, with a record date of April 21, 2026. Stockholders are asked to vote on three proposals: election of two directors (Board recommends FOR all nominees), ratification of CBIZ CPAs P.C. as independent auditors for the fiscal year ending December 31, 2026 (FOR), and an advisory vote to approve named executive officer compensation (FOR). A quorum requires holders of a majority of outstanding common stock present in person or by proxy.

• ·Proxy materials made available electronically on or about May 1, 2026; printed copies available upon request.
• ·Voting methods: in person, telephone, internet, or mail.
• ·Director election uses plurality voting; uncontested nominees must tender resignations if more WITHHOLD than FOR votes per Corporate Governance Guidelines.

23-04-2026

Trane Technologies plc filed its definitive proxy statement for the 2026 Annual General Meeting on June 4, 2026, in Adare, Ireland, seeking shareholder approval for electing 11 directors (10 independent), advisory approval of Named Executive Officer compensation, ratification of PricewaterhouseCoopers LLP as auditors, and renewal of directors' authorities to issue and reallot shares. The Board recommends voting FOR all six proposals, with record date of April 9, 2026. Board composition features diverse expertise in finance, global operations, and technology among nominees.

• ·Record date for voting eligibility: April 9, 2026.
• ·2027 Annual Meeting shareholder proposal deadlines: December 24, 2026 for inclusion in proxy statement; March 6, 2027 for business proposals and director nominations.
• ·April Miller Boise to leave Intel effective June 1, 2026.

23-04-2026

Caris Life Sciences, Inc. has issued its 2026 Proxy Statement for the virtual Annual Meeting of Shareholders on June 4, 2026, seeking election of ten director nominees to serve until the 2027 Annual Meeting, with the board size reducing from twelve to ten following the retirement of Drs. George H. Poste and Jonathan Knowles. Shareholders are also asked to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. No financial performance metrics or changes are discussed.

• ·Record Date: Close of business on April 9, 2026
• ·Annual Meeting: Thursday, June 4, 2026, at 10:00 a.m. Central Time, virtual at www.virtualshareholdermeeting.com/CAI2026
• ·Proxy materials sent/disseminated: April 23, 2026
• ·Election requires plurality vote; board not classified (one-year terms)

23-04-2026

Restaurant Brands International Inc. (RBI) filed its DEF 14A proxy statement for the 2026 Annual General Meeting on June 3, 2026, seeking shareholder approval to elect ten directors until the 2027 AGM, approve on a non-binding advisory basis the compensation of named executive officers, and appoint KPMG LLP as auditors until the 2027 AGM. The hybrid meeting will be held in person at Tim Hortons headquarters in Toronto or virtually online, with a record date of April 8, 2026. The filing includes XBRL-tagged pay versus performance disclosures for principal executive officers Mr. Cil and Mr. Kobza covering fiscal years 2021 through 2025, but no specific compensation figures are detailed in the provided content.

• ·Record Date: April 8, 2026
• ·Proxy submission deadline: 8:00 a.m. ET on June 2, 2026
• ·Pay vs. performance disclosures cover fiscal years 2021-2025 for PEOs and Non-PEO NEOs

23-04-2026

Camp4 Therapeutics Corporation (CAMP) has filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, scheduled virtually on June 10, 2026, at 11:00 a.m. EDT. Key proposals include the election of three Class II directors (Steven Holtzman, Murray Stewart, DM FRCP, and Richard Young, PhD) for three-year terms, ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and approval of Amendment No. 1 to the 2024 Equity Incentive Plan. The record date is April 13, 2026, with 51,925,800 shares of common stock outstanding; the Board recommends voting FOR all proposals.

• ·Annual Meeting is entirely virtual at www.virtualshareholdermeeting.com/CAMP2026; no physical location.
• ·Quorum requires holders of a majority of shares entitled to vote.
• ·Broker non-votes expected on Proposals 1 and 3; discretionary voting on Proposal 2.
• ·2025 Annual Report on Form 10-K filed with SEC on March 5, 2026.

23-04-2026

Amylyx Pharmaceuticals, Inc. (AMLX) filed a DEF 14A proxy statement on April 23, 2026, for its 2026 Annual Meeting of Stockholders, to be held virtually on June 4, 2026, at 9:00 a.m. Eastern Time via live webcast at www.meetnow.global/M75QLG2, with no in-person attendance option. The statement provides voting instructions for record and beneficial owners, including online at www.investorvote.com/AMLX, phone at +1 (800) 652-8683, or mail, and includes XBRL-tagged executive compensation data for Principal Executive Officers Justin Klee and Joshua Cohen covering 2023-2025. Proxy materials and the 2025 Annual Report are available online at www.envisionreports.com/AMLX.

• ·Virtual meeting platform supported on MS Edge, Firefox, Chrome, Safari; Internet Explorer not supported.
• ·Beneficial owners must register in advance by 5:00 p.m. ET on June 3, 2026, with legal proxy to attend and vote virtually.
• ·Principal executive offices: 55 Cambridge Parkway, Suite 6W, Cambridge, MA 02142.
• ·No telephone dial-in option for the meeting; webcast only.

23-04-2026

Chicago Atlantic Real Estate Finance, Inc. (REFI) has issued a proxy statement for its 2026 Annual Meeting on June 11, 2026, at 10:00 a.m. Central Time in Chicago, IL, where stockholders will vote to elect five directors (noted as seven in the shareholder letter) and ratify BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 2, 2026, with 21,207,228 shares of common stock outstanding, requiring a quorum of 10,603,614 shares; the Board unanimously recommends voting FOR both proposals. No financial performance metrics or period comparisons are provided in the filing.

• ·Voting methods: internet at www.proxyvote.com, telephone at 1-800-690-6903, or mail proxy card.
• ·Proxy materials and Form 10-K available at https://investors.refi.reit/financial-information/sec-filings.
• ·Director election requires plurality vote; auditor ratification requires majority of votes cast.
• ·Broker non-votes have no effect on proposals; brokers can vote on auditor ratification but not director election.

23-04-2026

Minerva Neurosciences, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 3, 2026 at 8:30 a.m. ET. Key proposals include electing two Class III directors (Dr. David Kupfer and Jan van Heek to serve until 2029), approving amendments to the Certificate of Incorporation to enable exculpation of certain officers and eliminate the exclusive forum provision, advisory votes on named executive officer compensation and say-on-pay frequency, and ratifying Deloitte & Touche LLP as auditors for FY 2026. As of the record date April 9, 2026, 43,841,998 shares of common stock and 3,296 shares of Series A Preferred Stock were outstanding.

• ·Annual Meeting accessible via live webcast at www.virtualshareholdermeeting.com/NERV2026; requires 16-digit control number.
• ·Stockholder list available for examination 10 days prior to meeting at principal offices or via email to info@minervaneurosciences.com, and during the meeting online.

23-04-2026

Lovesac Co (LOVE) filed its DEF 14A Definitive Proxy Statement on April 23, 2026, for the 2026 Annual Meeting of Stockholders, to be held virtually on June 9, 2026, at 10:00 a.m. ET via https://web.viewproxy.com/LovesacCompany/2026. Stockholders of record as of April 16, 2026, are entitled to vote on matters outlined in the proxy, with registration required by 11:59 p.m. ET on June 9, 2026. The notice is signed by Shawn D. Nelson, Founder and Chief Executive Officer.

• ·Fiscal year end: February 4
• ·Company address: 421 Atlantic Street, Suite 200, Stamford, CT 06901
• ·Business phone: 203-817-2279
• ·Record date: April 16, 2026
• ·Meeting registration deadline: 11:59 p.m. ET on June 9, 2026

23-04-2026

BK Technologies Corporation (BKTI) has filed its definitive proxy statement for the 2026 annual meeting of stockholders, to be held virtually on June 18, 2026, at 9:00 a.m. ET via www.virtualshareholdermeeting.com/BKTI2026. Stockholders of record as of April 21, 2026 (3,744,151 shares outstanding held by 144 record holders) will vote on electing seven directors, ratifying the independent auditor for fiscal 2026, and advisory approval of named executive officer compensation. E-proxy notices will be mailed on or about April 27, 2026, with proxy materials available online.

• ·Annual meeting purposes: (1) elect seven directors, (2) ratify independent registered public accounting firm for fiscal year ending December 31, 2026, (3) advisory 'say-on-pay' vote
• ·Proxy materials and Form 10-K for year ended December 31, 2025 available at www.proxyvote.com
• ·Virtual meeting login begins at 8:45 a.m. ET on June 18, 2026

23-04-2026

SELLAS Life Sciences Group, Inc. issued a DEF 14A proxy statement dated April 23, 2026, for its 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026, at 8:30 a.m. ET. Proposals include electing two Class I directors for a three-year term, ratifying Baker Tilly US, LLP as independent auditors for the fiscal year ending December 31, 2026, approving an amendment to increase shares under the 2023 Equity Plan by 20,000,000, advisory approval of named executive officer compensation, and authorizing adjournment if needed. As of the record date April 21, 2026, 184,532,574 shares of common stock were outstanding, requiring a quorum of 92,266,288 shares.

• ·Meeting held exclusively online via live webcast at www.virtualshareholdermeeting.com/SLS2026; no physical location.
• ·Stockholders of record as of April 21, 2026 entitled to vote; one vote per share of common stock.
• ·Proxy materials and 2026 Annual Report (Form 10-K for year ended December 31, 2025) available at www.proxyvote.com.
• ·List of stockholders available for inspection 10 days prior to meeting at company headquarters and during virtual meeting.

23-04-2026

Rapport Therapeutics, Inc.'s DEF 14A proxy statement outlines the virtual annual meeting on June 10, 2026, at 1:00 p.m. ET, where shareholders will vote to elect three Class II directors—James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D.—each to serve until the 2029 annual meeting, and to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 14, 2026, with 47,807,623 shares of common stock outstanding entitled to vote. Voting must occur by 11:59 p.m. ET on June 9, 2026, via internet, phone, mail, QR code, or during the virtual meeting at www.virtualshareholdermeeting.com/RAPP2026.

• ·Annual meeting quorum requires majority of voting power of outstanding shares.
• ·Proposal 1 (director election) is non-routine; broker non-votes have no effect.
• ·Proposal 2 (auditor ratification) is routine; advisory and non-binding.
• ·Company headquarters: 99 High Street, Suite 2100, Boston, MA 02110.

23-04-2026

Aclaris Therapeutics, Inc. filed its DEF 14A proxy statement for the virtual Annual Meeting of Stockholders on June 4, 2026, at 9:00 a.m. ET, with record date April 14, 2026. Agenda items include electing two director nominees to serve until the 2029 Annual Meeting, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as auditors for fiscal year ending December 31, 2026. As of the record date, 139,663,680 shares of common stock were outstanding and entitled to vote.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/ACRS2026 using 16-digit control number.
• ·Notice of Internet Availability mailed on or about April 23, 2026.
• ·Compensation disclosures reference equity awards for Dr. Walker (2024-2025) and Dr. Manion (2023-2024) as PEO/Non-PEO NEO, but no specific values provided.

23-04-2026

Ameresco, Inc. (AMRC) filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on June 4, 2026, at 10:00 a.m. ET, virtually via www.virtualshareholdermeeting.com/AMRC2026. Key proposals include electing two Class I directors for a three-year term, ratifying RSM US LLP as independent auditors for FY ending December 31, 2026, approving an amendment to the 2020 Stock Incentive Plan to add 3,200,000 shares, and an advisory vote on executive compensation. The record date is April 10, 2026, with 34,939,417 Class A shares (1 vote each) and 18,000,000 Class B shares (5 votes each) outstanding; the board recommends voting FOR all proposals.

• ·Notice of proxy materials mailed on or about April 24, 2026.
• ·Quorum requires majority of voting power represented; Proposal 3 requires majority of outstanding shares.
• ·Proposals 1, 3, and 4 are non-discretionary (broker non-votes possible); Proposal 2 is discretionary.

23-04-2026

Arrow Financial Corporation's DEF 14A proxy statement for the June 3, 2026 virtual annual meeting summarizes 2025 performance, including net income of $44.0 million ($2.65 per diluted share, +50% YoY EPS growth), net interest margin expansion to 3.19%, and tangible book value growth exceeding 10%, with Q4 ROAA surpassing 1.20%. The company completed its 'One Bank Weekend' integration, launching the unified Arrow Bank National Association brand. Community efforts reached over $1 million in giving to 424 organizations, supported by 13,700 employee volunteer hours.

• ·Proxy statement includes Pay vs. Performance disclosures for PEO (David S. DeMarco, Thomas J. Murphy) and Non-PEO NEOs covering 2021-2025.
• ·Annual Meeting at 10:00 a.m. on June 3, 2026, hosted virtually via arrowfinancial.com.

23-04-2026

Harvard Apparatus Regenerative Technology, Inc. (HRGN) filed a DEF 14A proxy statement for its 2026 Annual Meeting on June 18, 2026, at 9:30 a.m. ET, to elect three director nominees for one-year terms expiring at the 2027 annual meeting, ratify CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approve on a non-binding advisory basis the compensation of named executive officers. The record date is April 21, 2026, with 17,580,744 shares of common stock outstanding held by approximately 137 stockholders of record. The Board of Directors recommends voting 'FOR' all three proposals.

• ·Annual Meeting location: 84 October Hill Road, Suite 11, Holliston, MA 01746
• ·Notice of Internet Availability of Proxy Materials mailed on or about May 6, 2026
• ·Proxy materials and 2025 Form 10-K available at www.edocumentview.com/HRGN

23-04-2026

Local Bounti Corporation's proxy statement solicits votes for its 2026 Annual Meeting on June 10, 2026 (virtual format), for stockholders of record as of April 13, 2026 (22,795,198 common shares outstanding held by 41 record holders). Key proposals include electing two Class II directors, ratifying WithumSmith+Brown, PC as independent auditors for the year ending December 31, 2026, and approving for NYSE compliance the issuance of up to 7,882,861 shares upon conversion of a $15.0 million Note and up to 5,500,000 shares under a Warrant issued to majority stockholder U.S. Bounti pursuant to a March 13, 2026 Purchase Agreement. The Board recommends voting FOR all proposals; no financial performance metrics or period comparisons are provided.

• ·Note initial conversion price: $2.50 per share
• ·Warrant exercise price: $0.125 per share, exercisable immediately and expires 10 years from initial exercise date
• ·Purchase Agreement with U.S. Bounti dated March 13, 2026
• ·Annual Meeting exclusively virtual via live audiocast at virtualshareholdermeeting.com/LOCL2026, 9 a.m. Mountain Time
• ·Proxy materials notice mailed on or about April 23, 2026

23-04-2026

5C Lending Partners Corp. issued a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 16, 2026, with a record date of April 20, 2026. Key proposals include the election of Robert Gheewalla (by Preferred Stockholders) and Michael Koester (by Preferred and Common Stockholders) as Class II directors until 2029, ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, and an amendment to Section 7.2(a) of the Charter to reduce the stockholder vote threshold for certain liquidation proposals. The Board unanimously recommends voting 'FOR' all proposals; Preferred Stockholders' votes are controlled by irrevocable proxies granted under the September 26, 2024 Preferred Stock Subscription Agreement.

• ·Annual Meeting format: virtual only via www.virtualshareholdermeeting.com/5CLP2026
• ·Proxy materials and Form 10-K for year ended December 31, 2025 available at www.proxyvote.com
• ·Preferred Stock proxies are irrevocable and held by designated Proxy Holder(s)

23-04-2026

Lulu's Fashion Lounge Holdings, Inc. (LVLU) DEF 14A proxy statement discloses auditor fees from Deloitte & Touche LLP totaling $1,435,195 for FY ended December 28, 2025, down 2.5% from $1,472,195 in FY 2024, primarily due to lower audit fees ($1,433,300 vs. $1,470,300), while audit-related fees remained flat at $1,895. The filing details executive officers including CEO Crystal Landsem, President/CIO Mark Vos, and new CFO Heidi Crane; board composition with 6 members (4 independent); and major shareholder ownership as of April 15, 2026: H.I.G. Growth Partners (32.1%), CPPIB (17.5%), and IVP Holdcos (17.6%) under a Stockholders Agreement. Governance highlights include pre-approval policies and a disclosed personal relationship between CEO Landsem and President Vos.

• ·No tax fees or all other fees incurred in FY2025 or FY2024.
• ·Audit Committee pre-approved all services by Deloitte & Touche LLP.
• ·Board classified into three classes with staggered three-year terms; directors removable only by 66-2/3% stockholder vote.
• ·4 of 6 board members independent per Nasdaq standards.
• ·Stockholders Agreement provides director designation rights based on ownership thresholds; no designations for current annual meeting.

23-04-2026

LB Pharmaceuticals Inc. (LBRX) filed a DEF 14A proxy statement for its 2026 Annual Meeting, nominating three incumbent Class I directors—Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum—for reelection to three-year terms, while current director Zachary Prensky will retire and not stand for reelection, keeping the Board at nine members. The filing details biographies of all directors, emphasizing their deep expertise in biopharmaceutical R&D, commercial leadership, investment, and governance. No financial performance metrics are discussed.

• ·Board divided into three classes: Class I (expiring 2026), Class II (2027), Class III (2028).
• ·Zachary Prensky notified intent to retire on March 13, 2026.
• ·No director or executive officer related by blood, marriage, or adoption.
• ·Proxies may vote for substitutes if nominees unavailable.

23-04-2026

MariMed Inc. (MRMD) filed a DEF 14A Proxy Statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 4, 2026, at 9:30 a.m. ET. Shareholders of record as of April 10, 2026 (with 398,920,671 common shares outstanding) will vote on electing four directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—and advisory approval of M&K CPAs PLLC as independent auditors for the fiscal year ending December 31, 2026. No financial performance metrics or period comparisons are provided in the filing.

• ·Meeting accessible virtually at www.virtualshareholdermeeting.com/MRMD2026 using 16-digit control number.
• ·Proxy materials and Annual Report for year ended December 31, 2025 available at www.proxyvote.com.
• ·Quorum requires majority of common shares outstanding; Proposal 1 (directors) is plurality vote, Proposal 2 (auditors) is majority of votes cast.

23-04-2026

Edgewise Therapeutics, Inc., a late-stage biopharmaceutical company focused on muscle diseases, has filed its definitive proxy statement for the annual stockholder meeting on June 4, 2026, seeking election of three Class II directors (Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D.), ratification of KPMG LLP as independent auditors for fiscal year ending December 31, 2026, and an advisory vote approving named executive officer compensation. The proxy highlights robust corporate governance practices, including annual board assessments, executive sessions of independent directors, a compensation recovery policy, and active stockholder engagement. No financial performance metrics or period-over-period comparisons are disclosed in the filing.

• ·Annual meeting location: 1715 38th Street, Boulder, Colorado 80301
• ·Record date: April 9, 2026
• ·Christopher Martin appointed to board in November 2025, bringing commercial launch experience ahead of Becker muscular dystrophy launch and Phase 3 cardiovascular asset
• ·Board structure: three staggered classes, with Class II nominees serving until 2029 annual meeting

23-04-2026

Walmart's DEF 14A Proxy Statement for the June 4, 2026 Annual Shareholders’ Meeting details strong Fiscal 2026 performance, including $41.6 billion in operating cash flow, profits growing faster than sales, and $15.6 billion returned to shareholders via dividends and repurchases, supported by a new $30 billion share repurchase authorization. It announces a seamless CEO transition with John Furner succeeding Doug McMillon, alongside board changes such as Shishir Mehrotra joining as a director, Tim Flynn retiring, Bob Moritz assuming Audit Committee Chair, Marissa Mayer extending her term, and Brian Niccol not seeking re-election. The Board emphasizes disciplined investments in AI, technology, and omnichannel retail to drive future growth and value.

• ·Annual Shareholders’ Meeting scheduled for June 4, 2026, at 8:30 a.m. Central Time (virtual: www.virtualshareholdermeeting.com/WMT2026)
• ·John Furner joined the Board in November 2025; Doug McMillon retires from Board at end of term in June 2026
• ·Board refreshment includes Tim Flynn retiring post-meeting and Marissa Mayer extending service to 2027 Annual Meeting

23-04-2026

Design Therapeutics, Inc. (DSGN) has filed a DEF 14A proxy statement for its Annual Meeting, proposing the election of Simeon George, M.D., current Lead Independent Director, as the Class II director for a three-year term expiring at the 2029 Annual Meeting. The Board consists of seven members divided into three classes, with no reported changes to size or composition beyond this routine re-election. Board diversity stands at 43% women or racially/ethnically diverse individuals.

• ·Four directors attended the 2025 Annual Meeting: Pratik Shah, Ph.D.; Deepa Prasad; John Schmid; and Rodney Lappe, Ph.D.
• ·Board attendance policy invites directors and nominees to the Annual Meeting.
• ·Vacancies filled only by majority of remaining directors.

23-04-2026

Inmune Bio, Inc. (INMB) filed a DEF 14A proxy statement on April 23, 2026, for its Annual Meeting of Stockholders scheduled for June 16, 2026, at 10:00 AM ET via virtual webcast. The filing includes XBRL-tagged pay versus performance disclosures detailing equity award values, changes in fair value, vesting details, and exclusions for Principal Executive Officer (PEO) David Moss, former PEO RJ Tesi, and non-PEO NEOs across 2023-2025; no specific numerical values are provided in the filing excerpt. Proxies are solicited to David Moss and Cory Ellspermann.

• ·Annual Meeting via live webcast at www.virtualshareholdermeeting.com/INMB2026
• ·Fiscal year end: December 31
• ·State of incorporation: NV
• ·Business address: 225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432

23-04-2026

Vaxcyte, Inc. (PCVX) filed a DEF 14A proxy statement dated April 23, 2026, for its 2026 Annual Meeting of Stockholders to be held virtually on June 15, 2026 at 8:30 a.m. PT, with a record date of April 20, 2026 when 144,387,225 shares of common stock were outstanding, requiring a quorum of 72,193,613 shares. Stockholders will vote on three proposals: election of three Class III directors to serve until the 2029 Annual Meeting, ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, and advisory approval of named executive officer compensation. The proxy materials are available online, with voting deadlines of 11:59 p.m. EST on June 14, 2026.

• ·Annual Meeting accessible via live webcast at www.virtualshareholdermeeting.com/PCVX2026
• ·Proxy voting available by telephone (1-800-690-6903), internet (www.proxyvote.com), mail, or during the meeting
• ·Notice of Internet Availability mailed on or about April 23, 2026

23-04-2026

Antero Resources Corporation's 2026 Proxy Statement details the virtual annual meeting on June 3, 2026 (record date April 13, 2026), seeking shareholder approval to elect two Class I directors to serve until 2029, ratify KPMG LLP as auditors for the year ending December 31, 2026, and an advisory vote on 2025 executive compensation. 2025 performance included modest 1% net production growth (flat) with drilling and completion capital at the low end of guidance, a $301M net debt reduction lowering leverage by ~50%, and $166M in share repurchases, driving a 157.2% annual incentive payout while PSUs paid out between 81.59% and 200% of target. The company executed a smooth leadership transition with Michael N. Kennedy succeeding Paul Rady as CEO and President effective August 16, 2025.

• ·Long-term incentive awards: 50% performance-based equity (absolute TSR hurdles and leverage metrics), 50% time-based equity, vesting over several years
• ·Annual incentive plan metrics: operational strategy (capital expenditures, production volume), leverage goals, cash cost containment
• ·Proxy materials available electronically starting April 23, 2026

23-04-2026

EverQuote, Inc. filed its DEF 14A Proxy Statement on April 23, 2026, for the 2026 Annual Meeting of Stockholders, to be held virtually on June 4, 2026, at 10:00 a.m. ET. Proposals include election of seven directors by plurality vote, approval by majority of outstanding shares of an amendment to the Restated Certificate of Incorporation to adopt new Delaware officer exculpation provisions, and ratification by majority of votes cast of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. As of the April 7, 2026 record date, 31,769,000 shares of Class A common stock (1 vote per share) and 3,604,278 shares of Class B common stock (10 votes per share) were outstanding.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/EVER2026; online check-in opens 15 minutes prior.
• ·Voting methods: internet, telephone (by 11:59 p.m. ET June 3, 2026), mail, or during virtual meeting.
• ·Principal executive offices: 141 Portland Street, Cambridge, MA 02139.
• ·Quorum: majority of voting power of Class A and Class B common stock (voting together as single class).

23-04-2026

Freeport-McMoRan Inc.'s 2026 Proxy Statement reviews 2025 performance, highlighting strong financial results with $5.6B operating cash flows exceeding $3.9B capital expenditures (excluding $0.6B for PTFI downstream facilities) and net debt of $2.3B, alongside YoY increases in U.S. copper production and improved unit costs across regions. However, a major mud rush incident at Grasberg in September 2025 overshadowed safety improvements, despite TRIR hitting decade-best levels. The filing also covers executive compensation elements for Richard C. Adkerson and Kathleen L. Quirk across 2021-2025.

• ·Mud rush incident at Grasberg Block Cave in September 2025.
• ·Memorandum of Understanding with Indonesia Government in February 2026 for PTFI operating rights extension.
• ·First U.S. mine with fully autonomous haulage system at Bagdad.

23-04-2026

Inhibrx Biosciences, Inc. (INBX) filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 3, 2026, at 10:00 a.m. Pacific Time. Shareholders of record as of April 7, 2026, when 14,607,286 shares of common stock were outstanding, will vote on Proposal 1: election of Class II directors, and Proposal 2: ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. Proxy materials and the Annual Report on Form 10-K for the year ended December 31, 2025, are available at https://www.proxydocs.com/INBX.

• ·Virtual meeting registration required at https://www.proxydocs.com/INBX by 10:00 a.m. PT on June 3, 2026, using control number.
• ·Proxy distribution began on or about April 23, 2026.
• ·Board recommends voting 'FOR' both proposals.

23-04-2026

Versant Media Group, Inc. (VSNT), recently spun off from Comcast on January 2, 2026, is convening its 2026 Annual Meeting of Shareholders on June 25, 2026, to elect 10 director nominees (9 independent), ratify Deloitte & Touche LLP as independent auditors for fiscal 2026, approve an annual frequency for future say-on-pay votes, and approve the Employee Stock Purchase Plan. The company highlighted robust 2025 financial performance with $6.69B total revenue, $930M net income attributable to Versant, $2.42B adjusted EBITDA, and $2.18B standalone adjusted EBITDA, alongside a $0.375 quarterly cash dividend declaration and $1B share repurchase authorization. Operating highlights include strong viewership and partnerships across brands like MS NOW, CNBC, Golf Channel, and USA Network, with recent acquisitions of Free TV Networks and INDY Cinema Group.

• ·Record date for voting: April 14, 2026
• ·Annual Meeting: June 25, 2026, at 10:00 a.m. ET via www.virtualshareholdermeeting.com/VSNT2026
• ·MS NOW generated nearly 8 billion views across TikTok and YouTube and 140 million podcast downloads in 2025
• ·Golf Channel delivered over 2,000 hours of live coverage across 200+ events

23-04-2026

Definitive Healthcare Corp. has issued a proxy statement for its 2026 Annual Meeting on June 4, 2026, seeking stockholder approval to elect three Class II directors for three-year terms, ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, approve an amendment to the 2021 Equity Incentive Plan increasing authorized Class A Common Stock shares by 15,000,000 from 30,972,789 to 45,972,789, and conduct an advisory vote on Named Executive Officer compensation. The record date is April 13, 2026, with 105,456,979 Class A shares and 38,225,333 Class B shares outstanding. No financial performance metrics or period-over-period comparisons are disclosed in the filing.

• ·Annual Meeting location: 492 Old Connecticut Path, Suite 401, Framingham, MA 01701 at 2:00 PM Eastern Time.
• ·Proxy materials first made available on or about April 23, 2026.
• ·Stockholders of record as of April 13, 2026 are entitled to vote.

23-04-2026

Viant Technology Inc.'s DEF 14A proxy statement for the fiscal year ended December 31, 2025, details non-employee director compensation, with Max Valdes earning $247,505, Brett Wilson $559,419, and Vivian W. Yang $255,005, primarily from cash retainers and RSU grants. It proposes the election of Class II directors Chris Vanderhook and Brett Wilson and ratification of Deloitte & Touche LLP as auditors for FY2026, with total auditor fees of $2,069 thousand in 2025, slightly down from $2,100 thousand in 2024 despite a 4% increase in audit fees offset by a 14% decline in tax fees. The board consists of five members across three classes with staggered terms.

• ·Brett Wilson elected to board on May 10, 2025, effective May 12, 2025.
• ·Initial RSU grant fair value $340,000 vesting over 3 years; annual $170,000 vesting in 1 year.
• ·Deloitte has served as independent auditor since 2020.
• ·Board divided into 3 classes with staggered 3-year terms; Class II terms expire at upcoming Annual Meeting.
• ·Executive ages: Tim Vanderhook 45, Chris Vanderhook 47, Larry Madden 61.

23-04-2026

Astera Labs, Inc. filed its definitive DEF 14A proxy statement on April 23, 2026, for the 2026 Annual Meeting of Stockholders on June 4, 2026, at 8:00 a.m. PT at 2345 North First Street, San Jose, CA 95131. Record date stockholders holding 171,281,952 shares of common stock will vote on electing three Class II directors to serve until the 2029 annual meeting, ratifying PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, advisory approval of NEO compensation, and the frequency of future say-on-pay votes. Proxy materials are accessible via www.proxyvote.com, with voting deadlines of 11:59 p.m. ET on June 3, 2026, for internet/telephone proxies.

• ·Quorum requires majority in voting power of outstanding shares present in person, by remote communication, or by proxy.
• ·Proposal 1 (director election) decided by plurality of votes cast; Proposals 2-4 by majority of votes properly cast.
• ·Abstentions and broker non-votes have no effect on proposals.
• ·Paper proxy requests must be made by May 21, 2026.

23-04-2026

Mobile Infrastructure Corporation (BEEP) has issued a proxy statement for its 2026 Annual Meeting of Stockholders on June 18, 2026, seeking approval for three proposals: election of directors, ratification of the independent registered public accounting firm, and approval of the Amended and Restated Incentive Award Plan. The record date is April 10, 2026, with 41,192,464 shares of common stock outstanding and entitled to vote. The meeting will be held virtually, and proxy materials were made available on or about April 23, 2026.

• ·Annual Meeting held virtually via live audio webcast at www.virtualshareholdermeeting.com/BEEP2026 at 9:00 a.m. Eastern Time on June 18, 2026.
• ·Proxy materials and 2025 Form 10-K available at https://ir.mobileit.com/.
• ·Company qualifies as emerging growth company and smaller reporting company under Jumpstart Our Business Startups Act and Exchange Act rules.
• ·Voting deadline: 11:59 p.m. Eastern Time on June 17, 2026 for Internet/telephone voting.

23-04-2026

Dyne Therapeutics, Inc. issued its DEF 14A proxy statement for the 2026 Annual Meeting on June 5, 2026 (virtual at www.proxydocs.com/DYN), with record date April 7, 2026, seeking approval to elect Class III directors David Lubner, Brian Posner, and Jason Rhodes; advisory approval of named executive officer compensation; amendment to increase authorized common shares from 200,000,000 to 400,000,000; officer exculpation provision; and ratification of Deloitte & Touche LLP as auditors for FY ending December 31, 2026. The filing references compensation elements for PEO John G. Cox and other NEOs including Josh Brumm across 2022-2025 but provides no specific numerical values. No period-over-period financial metrics or performance changes are detailed.

• ·Annual Meeting exclusively virtual; advance registration required at www.proxydocs.com/DYN.
• ·Proxy materials and 2025 Annual Report (Form 10-K) available online; paper requests due by May 26, 2026.

23-04-2026

NWPX Infrastructure, Inc.'s definitive proxy statement for the June 10, 2026 virtual annual meeting seeks shareholder votes on electing directors, approving executive compensation on an advisory basis, and ratifying Baker Tilly US, LLP as independent auditors for 2026. Fiscal 2025 delivered record net sales of $526.0 million (up 6.8% YoY), record gross profit of $103.6 million, and record gross margin of 19.7%, driven by strong performance in Water Transmission Systems (WTS) and Precast segments amid robust infrastructure demand. The company highlights substantial free cash flow generation and a strengthened balance sheet, with no declines or flat metrics reported.

• ·Annual meeting virtually at www.virtualshareholdermeeting.com/NWPX2026 on June 10, 2026 at 7:00 a.m. Pacific Time.
• ·Record date: close of business April 9, 2026.
• ·Proxy materials mailed on or about April 23, 2026.
• ·Operates in two segments: Water Transmission Systems (WTS, brand Northwest Pipe Company) and Precast Infrastructure and Engineered Systems (brands NWPX Geneva and NWPX Park).

23-04-2026

OneSpan Inc.'s DEF 14A proxy statement, filed April 23, 2026, outlines the virtual annual stockholder meeting on June 5, 2026, to elect seven directors, approve advisory votes on named executive officer compensation and frequency, amend the Amended and Restated 2019 Omnibus Incentive Plan by adding 2,000,000 shares, and ratify KPMG LLP as auditor for fiscal 2026. The record date is April 8, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Virtual annual meeting at 11:00 a.m. Eastern Daylight Time via www.virtualshareholdermeeting.com/OSPN2026.
• ·Record date for voting: close of business on April 8, 2026.
• ·Proxy includes pay versus performance disclosures for PEOs from 2021-2025, with XBRL tags for equity awards and fair value adjustments.

23-04-2026

Solid Biosciences Inc. (SLDB) has issued a proxy statement for its Annual Stockholders Meeting on June 10, 2026, seeking approval for the election of three Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), advisory ratification of Ilan Ganot as a Class I director, ratification of PricewaterhouseCoopers LLP as auditors for FY 2026, an amendment to increase authorized common shares from 240,000,000 to 480,000,000, and an advisory vote on executive compensation. As of the Record Date April 16, 2026, there were 98,413,277 shares of common stock outstanding. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting to be held virtually at http://www.virtualshareholdermeeting.com/SLDB2026 on June 10, 2026 at 8:00 a.m. Eastern Time
• ·Record Date: April 16, 2026
• ·Notice mailing scheduled to begin on or about April 23, 2026

23-04-2026

Surgery Partners, Inc. (SGRY) filed its DEF 14A definitive proxy statement on April 23, 2026, for the virtual annual meeting of stockholders on June 5, 2026, at 10:00 a.m. CDT. Key items include electing three Class II directors for three-year terms, an advisory vote to approve named executive officer compensation, and ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is April 8, 2026, and no financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Virtual meeting access: www.meetnow.global/MRTVYKW with 15-digit control number
• ·Registration deadline for beneficial owners: 4:00 p.m. CDT on June 2, 2026
• ·Investor Relations: 340 Seven Springs Way, Suite 600, Brentwood, Tennessee 37027; (615) 234-5900; ir@surgerypartners.com
• ·Proxy materials available at www.investorvote.com/SGRY and www.surgerypartners.com

23-04-2026

BioCryst Pharmaceuticals, Inc. filed a definitive proxy statement for its Annual Meeting of Stockholders on June 11, 2026, proposing the election of three directors for terms ending in 2029, ratification of Ernst & Young LLP as independent auditors for 2026, a non-binding advisory vote on executive compensation, and approval of an amended Stock Incentive Plan to increase shares available for issuance. The record date is April 13, 2026, with 254,105,895 shares of common stock outstanding. The Board unanimously recommends voting in favor of all proposals.

• ·Meeting location: 4505 Emperor Blvd., Suite 200, Durham, NC 27703 at 10:00 a.m. Eastern Daylight Time
• ·Directors elected by plurality vote
• ·Quorum requires majority of outstanding shares present in person or by proxy

23-04-2026

Pluri Inc.'s DEF 14A proxy statement discloses executive compensation for FY2025 (ended June 30, 2025), with CEO Yaky Yanay's total compensation rising 103% YoY to $1,502,758 from $741,479, driven by share-based awards of $944,341 (up 137% YoY), despite salary reductions due to armed conflict in Israel. Former CFO Chen Franco-Yehuda's FY2025 total compensation declined to $326,883 from $492,366 in FY2024 amid her departure, while new CFO Liat Zalts received $589,680 for partial-year service. Two delinquent Section 16(a) filings were noted for Alexandre Weinstein and Chutzpah Holdings Ltd.

• ·Delinquent Section 16(a) filings: Form 3 by Alexandre Weinstein filed February 18, 2025; Form 4 by Alexandre Weinstein and Chutzpah Holdings Ltd. filed July 1, 2025.
• ·CEO salary reductions: 20% for Jan-Feb 2024 (NIS 39,600/month) and 25% for Jul-Dec 2025.
• ·Former CFO employment ended March 31, 2025.
• ·Equity grants to CEO in October 2025: 39,050 fully vested RSUs and options to purchase 39,050 shares.

23-04-2026

MercadoLibre's 2026 Proxy Statement discloses leadership transitions effective January 1, 2026, with Marcos Galperin moving to Executive Chairman and Ariel Szarfsztejn appointed as CEO; new roles include Daniel Rabinovich as President of Technology and Operations, Agustín Costa as EVP Shipping, and Fernando Yunes as EVP Marketplace. No related party transactions exceeding $120,000 occurred in fiscal year 2025. Beneficial ownership as of April 14, 2026, shows 5% holders Baillie Gifford & Co. (7.46%) and Galperin Trust (7.00%), with directors and executives holding less than 1% collectively.

• ·All Section 16(a) filing requirements were met timely for 2025, with minor delays in Forms 3 for new Section 16 officers Agustín Costa and Fernando Yunes (filed January 13, 2026, due January 12, 2026).
• ·Company has indemnification agreements with all directors and executive officers to the fullest extent permitted by Delaware law.

23-04-2026

Universal Display Corporation's DEF 14A Proxy Statement, filed April 23, 2026, solicits votes for the election of all 11 incumbent directors at the 2026 virtual Annual Meeting. The Nominating & Corporate Governance Committee has added three new Board members since March 2024 to bring fresh business and technical expertise. Steven V. Abramson, President and CEO, is nominated alongside the others, noted for his leadership in advancing OLED technologies globally.

• ·Annual Meeting held entirely online at www.virtualshareholdermeeting.com/OLED2026
• ·Shareholders vote by telephone, internet, mail, or online during meeting using 16-digit control number
• ·Series A Nonconvertible Preferred Stock holder waived director nomination rights
• ·XBRL tags reference compensation elements for PEO and Non-PEO NEOs across 2021-2025, including equity awards, fair values, vesting, and adjustments (no numeric values provided)